Handelsavisen
prelaunch
Companies Healthcare PVCT.PK
PV
PVCT.PK OTC Pharmaceuticals & Medical Research

Pvct.Pk

$0,06
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-1 575,3 %
ROE
86,2 %
Net margin
-1 615,8 %
Debt / equity
-0,45
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

PVCT.PK operates in the biotechnology and medical research industry, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of medical products and services.

Business. PVCT.PK operates in the biotechnology and medical research industry, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of medical products and services.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
86,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PVCT.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PVCT.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    PVCT.PK operates in the biotechnology and medical research industry, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of medical products and services.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    PVCT.PK exhibits a highly leveraged capital structure, with total liabilities of $6,996,240 and total equity of -$6,298,740, resulting in a negative debt-to-equity ratio of -0.45. The company's liquidity position is weak, as indicated by a current ratio of 0.08, and it holds only $251,290 in cash and equivalents, which is insufficient to cover its $2,851,390 in long-term debt. The company's free cash flow is negative at -$5,503,260, and its operating cash flow is also negative at -$3,325,990, suggesting significant cash outflows.

    Profitability is severely challenged, with a net loss of -$5,430,850 and an operating loss of -$5,294,760. The return on assets is -7.7862, and the return on equity is 0.8622, which is unusually high given the negative equity, likely due to the mathematical artifact of dividing a negative net income by a negative equity base. These metrics indicate that the company is not generating returns that meet industry expectations.

    PVCT.PK's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. The company's revenue of $336,110 is relatively small, and there is no indication of geographic expansion or diversification in the segments or regions it operates in.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The negative operating and net income, combined with the lack of positive cash flows, suggests that the company is not currently in a growth phase. The absence of a clear growth strategy or significant revenue increases in the near term indicates a challenging outlook for PVCT.PK.

    PVCT.PK faces significant financial risks, including a high liquidity risk due to its negative working capital and insufficient cash reserves to cover its obligations. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the company's negative net cash position after subtracting total debt is a key flag. The company has not made any adjustments to its valuation metrics, and there is no indication of recent dilutive events.

    Recent events related to PVCT.PK include the filing of its latest financial statements, which disclose the company's poor financial performance and liquidity challenges. There are no recent transcripts or other disclosures that provide additional insight into the company's operations or strategic direction. The lack of positive developments or strategic initiatives in the recent filings suggests that the company is facing ongoing operational and financial difficulties.

    Key takeaways
    • PVCT.PK has a highly leveraged capital structure with a negative debt-to-equity ratio and insufficient liquidity to meet its obligations.
    • The company is experiencing significant financial losses, with a net loss of -$5,430,850 and an operating loss of -$5,294,760.
    • PVCT.PK's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • The company's growth trajectory is uncertain, with no clear signs of improvement in its financial performance or cash flows.
    • PVCT.PK faces significant liquidity risks and has a negative net cash position after subtracting total debt.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,06
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$6.3M
    Net cash
    -$2.6M
    Current ratio
    0.1
    Debt / equity
    -0.5
    ROA
    -7.8%
    ROE
    86.2%
    Cash conversion
    61.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Dermatologicals
    low · business_description · 2026-07-04
    Hematology Drugs
    low · business_description · 2026-07-04
    Oncology Pharmaceuticals
    low · business_description · 2026-07-04
    Ophthalmology Drugs
    low · business_description · 2026-07-04
    Vaccine Adjuvants
    low · business_description · 2026-07-04
    Wound Care Products
    low · business_description · 2026-07-04

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals & Medical Research15,2B node revenueKLAR 23,0%BNTX 21,4%EXEL 15,2%MDGL 6,3%INSM 4,0%VCYT 3,4%MDXG 2,8%AVIR 2,3%Other 21,6%
    Source: company disclosures · own-taxonomy revenue-covered setPVCT 0,0% · rank #85 of 109

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs PVCT · multiples and returns
    KL
    KLAR
    KLAR.ST
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BN
    BNTX
    Biontech SE
    $92,25
    23,3B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    EX
    EXEL
    Exelixis Inc
    $55,06
    14,7B USD
    P/E
    19,5x
    vs self
    Div yield
    vs self
    ROE
    40,4 %
    vs self
    MD
    MDGL
    Madrigal Pharmaceuticals Inc
    $482,00
    11,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -47,8 %
    vs self
    IN
    INSM
    Insmed Inc
    $107,46
    23,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -160,2 %
    vs self
    VC
    VCYT
    Veracyte Inc
    $45,30
    3,6B USD
    P/E
    55,5x
    vs self
    Div yield
    vs self
    ROE
    5,1 %
    vs self
    MD
    MDXG
    Mimedx Group Inc
    $4,27
    636,0M USD
    P/E
    11,1x
    vs self
    Div yield
    vs self
    ROE
    18,9 %
    vs self
    AV
    AVIR
    Atea Pharmaceuticals Inc
    $4,61
    P/E
    vs self
    Div yield
    vs self
    ROE
    -57,5 %
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-1 575,3 %Below median
    Net Margin-1 615,8 %Below median
    ROE86,2 %Best in class
    D/E-0,45Best in class
    Cash Conv0,61Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • PVCT.PK Market data — financials · 2026-05-29

    Ownership & reference

    Leadership

    • Ed V. PershingChairman of the Board, Chief Executive Officer

    Insider activity

    — missing data

    Short positioning

    802.8Kshares short+10237.3% vs prior
    1.47days to cover
    4.4Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PVCT.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Return on equity (FY 2025-12-31): -87.4%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -7.5%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -16.8%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -1.3%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 15.6%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -18.3%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): -1.11xDerived (calculated)
    • Current ratio (FY 2025-12-31): 0.08xDerived (calculated)
    • Return on assets (FY 2025-12-31): 789.3%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -5.7%Derived (calculated)
    • Net margin (FY 2025-12-31): 1,637.9%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -45.5%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 0.4%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -30.7%Derived (calculated)
    • EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
    • Revenue (annual): USD 336.11KSEC XBRL filing
    • Operating cash flow (annual): USD -3.33MSEC XBRL filing
    • Pre-tax income (annual): USD -5.51MSEC XBRL filing
    • Net income (annual): USD 5.51MSEC XBRL filing
    • Interest expense (annual): USD 5.34KSEC XBRL filing
    • Shares outstanding (annual): 420.28MSEC XBRL filing
    • Cash & equivalents (annual): USD 251.29KSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage